pre-IPO PHARMA

nflection-therapeutics PRESS RELEASE ARCHIVE

Oct 18, 2021

NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases


May 26, 2021

NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial


Jun 9, 2020

NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis


Google Analytics Alternative